Program
Pramipexole
Also written as “pramipexole”, “Pramipexole Dihydrochloride” and “Pramipexole Immediate Release”.
Its studies are mostly in Parkinson Disease · Restless Legs Syndrome · Tourette Syndrome · Depressive Disorder, Major · Obsessive-Compulsive Disorder, led by 6 companies.
Drug pagePramipexole: every studyMany companies study it; this page follows only the 43 they lead. All 81 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Boehringer Ingelheimits history only | 360 open or running | phase 4since Sep 2, 2005 | Aug 22, 2005 | none ahead |
| Teva Pharmaceutical Industriesits history only | 30 open or running | phase 4since Nov 10, 2006 | Nov 10, 2006 | none ahead |
| Chase Therapeuticsits history only | 11 open or running | phase 2since Jul 5, 2018 | Jul 5, 2018 | none ahead |
| GlaxoSmithKlineits history only | 10 open or running | phase 1since May 8, 2007 | May 8, 2007 | none ahead |
| Haisco Pharmaceutical Groupits history only | 10 open or running | phase 1since Apr 2, 2026 | Apr 2, 2026 | none ahead |
| Novartisits history only | 10 open or running | phase 4since Aug 23, 2012 | Aug 23, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 25 studies since Aug 22, 2005.
- Mar 27, 2008Phase 3 study in Restless Legs SyndromeBoehringer Ingelheim · NCT00654498 · 306 enrolled · China
- May 19, 2008Phase 3 study in Tourette SyndromeBoehringer Ingelheim · NCT00681863 · 45 enrolled · United States, Germany
- May 29, 2008Phase 2 study in FibromyalgiaBoehringer Ingelheim · NCT00689052 · 61 enrolled · United States
- Feb 22, 20102 phase 1 studies in HealthyTeva Pharmaceutical Industries · NCT01074463, NCT01074450
- Aug 30, 2010Phase 3 study in Parkinson DiseaseBoehringer Ingelheim · NCT01191944 · 475 enrolled · China
- Oct 1, 2010Phase 1 study in HealthyBoehringer Ingelheim · NCT01214109 · 24 enrolled · China
- Aug 23, 2012Novartis’s first study: phase 4 study in Parkinson DiseaseNew to NovartisNovartis · NCT01673724 · 121 enrolled · Korea, Republic of
- Jun 20, 20142 phase 3 studies in Parkinson DiseaseBoehringer Ingelheim · NCT02172573, NCT02177357
- Sep 4, 2014Phase 4 study in Parkinson DiseaseBoehringer Ingelheim · NCT02233023 · 705 enrolled
- Oct 9, 20143 phase 1 studies in HealthyBoehringer Ingelheim · NCT02262546, NCT02261103, NCT02264132
- Apr 11, 2018Phase 4 study in Parkinson DiseaseBoehringer Ingelheim · NCT03521635 · 98 enrolled · China
- Jul 5, 2018Chase Therapeutics’ first study: phase 2 study in Depressive Disorder, MajorNew to Chase TherapeuticsChase Therapeutics · NCT03642964 · 24 enrolled · United States
- Apr 2, 2026Haisco Pharmaceutical Group’s first study: phase 1 study in HealthyNew to Haisco Pharmaceutical GroupHaisco Pharmaceutical Group · NCT07519278 · 49 enrolled · China
- Jul 22, 2026Phase 1 study in HealthyBoehringer Ingelheim · NCT07727785 · 25 enrolled · Germany
TargetBeta
“D2-like dopamine receptor agonist”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| rotigotinerule | UCB | phase 4 | 64 |
Studies
All 43 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07727785Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Sep 10, 2026 | 25 |
| NCT07519278Healthy · China | 1 | Completed | Haisco Pharmaceutical Group | Apr 11, 2017 | 49 |
| NCT03642964Depressive Disorder, Major · United States | 2 | Active, not recruiting | Chase Therapeutics | Dec 30, 2025 | 24 |
| NCT03521635Parkinson Disease · China | 4 | Completed | Boehringer Ingelheim | Jan 7, 2020 | 98 |
| NCT02264132Healthy | 1 | Completed | Boehringer Ingelheim | Nov 2006 | 24 |
| NCT02262546Healthy | 1 | Completed | Boehringer Ingelheim | Oct 2007 | 60 |
| NCT02261103Healthy | 1 | Completed | Boehringer Ingelheim | Jul 2006 | 39 |
| NCT02233023Parkinson Disease | 4 | Completed | Boehringer Ingelheim | Jun 2000 | 705 |
| NCT02177357Parkinson Disease | 3 | Completed | Boehringer Ingelheim | Jan 2000 | 150 |
| NCT02172573Parkinson Disease | 3 | Completed | Boehringer Ingelheim | Jul 2000 | 315 |
| NCT01673724Parkinson Disease · Korea, Republic of | 4 | Completed | Novartis | May 23, 2016 | 121 |
| NCT01214109Healthy · China | 1 | Completed | Boehringer Ingelheim | Jan 2011 | 24 |
| NCT01191944Parkinson Disease · China | 3 | Completed | Boehringer Ingelheim | Jan 2012 | 475 |
| NCT01074463Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Mar 2005 | 24 |
| NCT01074450Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Mar 2005 | 24 |
| NCT00689052Fibromyalgia · United States | 2 | Terminated | Boehringer Ingelheim | Nov 2008 | 61 |
| NCT00681863Tourette Syndrome · United States, Germany | 3 | Terminated | Boehringer Ingelheim | Oct 2009 | 45 |
| NCT00654498Restless Legs Syndrome · China | 3 | Completed | Boehringer Ingelheim | Jun 2009 | 306 |
| NCT00601523Parkinson Disease · United States, Austria, Czech Republic and more | 3 | Completed | Boehringer Ingelheim | Jun 2010 | 511 |
| NCT00577460Parkinson Disease · Austria, Czech Republic, Hungary and more | 3 | Completed | Boehringer Ingelheim | Jun 2010 | 391 |
| NCT00560508Parkinson Disease · Japan | 3 | Completed | Boehringer Ingelheim | Nov 2009 | 112 |
| NCT00558467Tourette Syndrome · United States, Germany | 2 | Completed | Boehringer Ingelheim | Jun 2009 | 63 |
| NCT00558025Parkinson Disease · France, Germany, Netherlands | 3 | Completed | Boehringer Ingelheim | May 2008 | 156 |
| NCT00479401Parkinson Disease · United States, Argentina, Austria and more | 3 | Completed | Boehringer Ingelheim | Nov 2008 | 539 |
| NCT00472199Restless Legs Syndrome · Austria, Belgium, Finland and more | 4 | Completed | Boehringer Ingelheim | Jul 2008 | 331 |
| NCT00471588Obsessive-Compulsive Disorder · United Kingdom | 1 | Completed | GlaxoSmithKline | Dec 2007 | 52 |
| NCT00466167Parkinson Disease · Austria, Czech Republic, Hungary and more | 3 | Completed | Boehringer Ingelheim | Nov 2008 | 517 |
| NCT00402233Parkinson Disease · United States | 4 | Completed | Boehringer Ingelheim | Sep 2008 | 312 |
| NCT00399477Parkinson Disease | 4 | Completed | Teva Pharmaceutical Industries | Jul 2007 | 200 |
| NCT00390689Idiopathic Restless Legs Syndrome · Japan | 3 | Completed | Boehringer Ingelheim | Mar 2008 | 154 |
| NCT00375284Restless Legs Syndrome · United States | 4 | Completed | Boehringer Ingelheim | Jul 2007 | 404 |
| NCT00356096Restless Legs Syndrome · Finland, France, Germany and more | 4 | Completed | Boehringer Ingelheim | Jun 2007 | 404 |
| NCT00349531Restless Legs Syndrome · Denmark, Finland, Germany and more | 4 | Completed | Boehringer Ingelheim | May 2007 | 369 |
| NCT00321854Parkinson Disease · United States, Austria, Finland and more | 4 | Completed | Boehringer Ingelheim | Apr 2009 | 535 |
| NCT00297778Parkinson Disease · Austria, Finland, France and more | 4 | Completed | Boehringer Ingelheim | May 2008 | 296 |
| NCT00275457Restless Legs Syndrome · Austria, Germany, Netherlands and more | 3 | Completed | Boehringer Ingelheim | Apr 2004 | 346 |
| NCT00240409Parkinson Disease · China | 3 | Completed | Boehringer Ingelheim | Aug 2004 | 208 |
| NCT00239486Restless Legs Syndrome · Finland | 2 | Completed | Boehringer Ingelheim | Apr 2004 | 109 |
| NCT00152997Restless Legs Syndrome · Japan | 2 | Completed | Boehringer Ingelheim | Dec 2005 | 41 |
| NCT00152958Restless Legs Syndrome · Germany | 3 | Completed | Boehringer Ingelheim | Feb 2005 | 224 |
| NCT00144300Parkinson Disease · United States | 4 | Completed | Boehringer Ingelheim | Sep 2010 | 246 |
| NCT00144209Restless Legs Syndrome · Switzerland | 3 | Completed | Boehringer Ingelheim | Feb 2005 | 58 |
| NCT00133198Restless Legs Syndrome · United States | 3 | Completed | Boehringer Ingelheim | Feb 2005 | 345 |
How it is read
Names in the registry
- “Pramipexole”, 15 entries
- “pramipexole”, 5 entries
- “Pramipexole Dihydrochloride”, 4 entries
- “Pramipexole Immediate Release”, 2 entries
- “Pramipexole Extended Release”, 2 entries
Conditions, from the studies’ own filings
- Parkinson Disease, 19 studies
- Restless Legs Syndrome, 12 studies
- Tourette Syndrome, 2 studies
- Depressive Disorder, Major, 1 study
- Obsessive-Compulsive Disorder, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.